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Abstract
Even a modestly effective  HIV-1 vaccine  would be highly  billion (US$  245 million). To maintain the vaccination
useful in India and could avoid millions of deaths.  How  rate  in the 11-14 year old cohort,  an additional 6.77
should such a vaccine  be introduced?  Based on evidence  million  in that age range would have to be vaccinated
of adoption of other vaccines in India, current levels of  each year,  at a vaccine  cost of Rs.  3.39 billion (US$  67.5
spending on them and coverage of prevention programs  million).
targeting both high- and low-risk groups, Seshadri,  An HIV-1 vaccine  will greatly reduce HIV/AIDS  in
Subramaniyam,  and Jha assess the potential demand  for  India, but it will not be a panacea.  There will be a
and strategic  use of an HIV-1 vaccine  in the four  continued need for effective  prevention  programs to
southern  Indian states of Andhra Pradesh,  Karnataka,  guard against behavior reversals or an imperfect  vaccine.
Maharashtra,  and Tamil Nadu. The authors also  discuss  Key inputs for prevention, immunization,  and treatment
potential strategies  for delivery of the vaccine,  programs such as identification of various groups that
prioritization  for vaccination,  and the political  economy  could be immunized  (vulnerable groups or general
of such a vaccine  in India. Assuming a vaccine  cost of  populations), strengthened  surveillance,  capacity
$10 a dose and including estimated  delivery costs, the  building,  operations research,  and evaluation at local
total cost of vaccinating 21.6 million adolescents  11-14  levels will continue to require intensive support.
years of age and 1 percent of adults would be  Rs.  12.25
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This paper assesses the potential demand for and strategic use of an HIV- 1 vaccine in
southern India. 1 The paper assesses the size of potential high- and low-risk target groups for
an HIV-1  vaccine in the 117 districts of Andhra Pradesh, Maharasthra,  Karnataka, and Tamil
Nadu. It also discusses potential strategies for delivery of the vaccine, prioritization for
vaccination, and the political economy of such a vaccine  in India. The latter issue includes a
discussion of the current level of knowledge and existing level of stigma as barriers to
demand for a vaccine,  even if it were offered free of charge. In reviewing these data, the paper
draws from examples of coverage of prevention programs targeting both high- and low-risk
groups, of adoption of other vaccines  in India and current levels of spending on them. An
HIV-  1 vaccine will greatly reduce HIV/AIDS  in India, but it will not be a panacea.  There will
be a continued need for effective prevention programs to guard against behavior reversals or
an imperfect vaccine.
2.  The HIV-1  Epidemic in Southern India
The Indian  government estimates that in 2000, 3.86 million Indians were living with
HIV-1, the second largest number of infected people after South Africa (NACO 2000).  While
HIV is transmitted via all major modes of transmission in India, the engine of the Indian
epidemic is heterosexual  transmission from vulnerable groups, 
2 chiefly commercial  sex
workers and their clients. The prevalence of HIV-1  in India may seem relatively low,-at 0.7
percent of the general adult population,  compared with rates of 20 percent and higher in
Botswana, South Africa, and Zimbabwe. Nevertheless, HIV has now been detected in all
states and union territories.  It has spread from sex workers and transport workers to women in
the general population,  and from urban to rural areas. If effective prevention efforts are not
implemented and sustained over the long term, mathematical  models suggest that India could
have over 30 million people infected by 2010 (Nagelkerke and de Vlas 2003).
The four southern states of Andhra Pradesh, Karnataka, Maharashtra,  and Tamil Nadu
account for nearly two-thirds of all HIV infections in India, even though they have less than
30 percent of the total population (Table  1). These four states have among the highest
infection rates: a median of 1.3-2.2 percent of women attending antenatal  clinics and 14-24
percent of patients attending public facilities for the treatment of sexually-transmitted
infections (STI) are infected with HIV-1.
' Throughout the text, we refer to HIV- I as this is  the most common in India and research  on differences
between HIV-I  and HIV-2 is  at an early stage in India (Sahni and others 2002).
2  Vulnerable  groups are defined as those who, because of risky sexual behavior,  are at increased  risk of
acquiring and transmitting HIV-I  infection. Chiefly, this refers to female sex workers, and their male clients, as
well as to injecting drug users where relevant.Table 1. Plopeunation  and IHIV  PrevaRence  in Souteierun  Rindia
Median HIV-1 prevalence (1998)
Estimated number  Sexually transmitted
Population in  of  HI  V-I  infected  Antenatal clinic  disease clinic
State  millions (2001)  adults (1998)  attendees  attendees
Andhra Pradesh  75.7  950,000  2.18  22.71
Karnataka  52.7  430,000  1.75  14.38
Maharashtra  96.7  790.000  2.23  24.03
Tamil Nadu  62.1  300,000  1.31  15.84
Southern  states  288.5  2,470,000  1.93  20.05
1Indis  1027.0  3,860,000  0.90  9.45
Source: Author's calculations based on NACO data for the 2001 Population Census and  1998 National Sentinel
Surveillance data. More recent antenatal clinic (ANC) data suggest lower infection levels,  especially  for
antenatal  clinic attendees. Given ANC data could well under- represent prevalence  (Thomas and others 2002),
we have used the earlier higher figures.
The development of a safe and effective preventive AIDS vaccine is becoming  a
global health priority, particularly in the developing world where HIV is spreading most
rapidly. Recent modeling of the impact of an HIV/AIDS vaccine in southern India found that
a vaccine that confers  100 percent protection for a lifetime in 95 percent of all vaccine
recipients could almost eradicate HIV-1  within 25 years (Nagelkerke  and de Vlas 2003). The
impact of a highly effective vaccine would be high, even if commercial  sex workers (CSW)
and their clients discontinued condom use ("disinhibition").  If high-risk populations were
targeted with such a vaccine and assuming disinhibition, adult HIV- 1 prevalence in southern
India in 2033 would reach  1.4 percent,  while it would rise to 2.1 percent if the general
population were targeted.3 On the other hand, a vaccine that confers 50 percent protection in
50 percent of recipients would have less of an impact and preventing  disinhibition would be
key. Assuming no disinhibition, adult HIV-1  prevalence  would reach 3.7 percent in 2033 if
high-risk groups are targeted with this less-effective  vaccine, and 4.6 percent if the general
population is targeted. The effects of this less-effective  vaccine could be reversed by
disinhibition, with adult HIV-1  prevalence in 2033 of 10.3 percent if high-risk groups are
targeted with the vaccine and  10.0 percent if the general population is targeted.
A brainstonming session on HIV- I vaccine development  by India was held in New
Delhi in November  1998 among scientists working on an HIV- 1 vaccine in India and abroad
(World Bank  1999). All of the experts were of the view that India should initiate a program
on HIV-  vaccine development in collaboration with international scientists, keeping in view
the various aspects of clinical trials and ethical issues.  Subsequent meetings have resulted in
the drafting of a Memorandum of Understanding  between the International  AIDS Vaccine
Initiative and the Government of India represented by the Indian Council of Medical  Research
(ICMR) and the National AIDS Control Organization (NACO) for accelerating development
3  Nagelkerke and de VIas (2002) assume that in the absence of a vaccine adult HIV- I prevalence would
reach 5 percent by 2033.
2of an AIDS vaccine applicable for use in India (IAVI website:
http://www.iavi.org/highlights/82/oldH200  1-03-20_India_VDP_Launch.htm).
3.  Experience with Other Vaccines  in India
The experience of the implementation of the routine childhood immunization program
in India provides valuable lessons for the introduction of an AIDS vaccine.  Even though early
generation HIV- 1 vaccines may not be suitable  for use with children under five, the coverage
and service delivery modalities help in understanding  the scope of the challenge of
introducing a new vaccine in the Indian context.
India started with a Universal Immunization Program for children under 5 years of age
in the 1  970s, then went on to a phase of the Expanded Program of Immunization (EPI), which
has become a part of the Reproductive  and Child Health (RCH) program.  The RCH program
includes not only immunization against the six vaccine preventable diseases for children,4 but
also tetanus toxoid for adolescent girls and pregnant women.  It further includes some
experiments  with neo-natal tetanus and hepatitis-B immunization in Andhra Pradesh state.5
The Indian Academy of Paediatrics has advocated the use of hepatitis B vaccine  as
part of the routine immunization schedule.  Many doctors in the private sector, therefore,  do
administer hepatitis  B vaccine to patients and children under their care. In addition, several
schools and non-governmental  organizations have been organizing hepatitis B vaccine drives
on a payment basis. However, this vaccine has not yet reached the poorer populations,
whether urban or rural. The Government of India does support planned state programs for the
introduction of the hepatitis B vaccination as part of the routine immunization program. The
states of Kerala, Haryana, Delhi, and Andhra Pradesh are all piloting hepatitis B, with the
largest coverage (about a third of the state) in Andhra Pradesh.6 During the recent past,
hepatitis B vaccine has been generally available in the private sector hospitals in the urban
areas to those who can afford it.
A key lesson from a review of the addition of new vaccines like Hepatitis B and
Haemophilus influenza type b in Asia suggests that strengthening  routine immunization
programs can raise the coverage for newer vaccines and that introduction of newer vaccines
can stimulate broader coverage of existing immunization programs (Olivera-Cruz and others
4 BCG, Diptheria-Pertussis-Tetanus  (DPT), OVC, measles.
s India has hepatitis B surface antigen  (HbsAg) prevalence between 2 and  10 percent among the
populations studied and prevalence  does not vary significantly  by the different regions of  the country. More than
40 million Indians are estimated to be carrying HbsAg.  Of the estimated  25 million babies born every year, over
one million run the lifetime risk of developing chronic hepatitis B virus (HBV) infection. Estimates also indicate
that annually over 100,000 Indians die due to illness related to HBV infection (Lodha  and others 2001).
6 The Government of Andhra Pradesh's Partnership Project for hepatitis B vaccine and strengthening of
routine immunization  with the Children's  Vaccination Program of Program for Appropriate  Technology  in
Health (PATH).
32001). For example, routine immunization coverage rose in Thailand after Hepatitis B
vaccination was introduced. Reviews  have also found that successfully adding a new vaccine
is predicated on having reasonable coverage of existing vaccines.
In India, adoption of different EPI vaccines  is a joint decision of national and state
governments.  In 1999-2000, total GOI recurrent EPI expenditures  amounted to Rs. 2,070
million (about US$ 42 million). (MOHFW 2001). Of this, about 47 percent, or Rs. 978
million (US$20 million), was spent on vaccines,  about 30 percent, or Rs.  634 million (US$ 13
million) on salaries of staff, about  14 percent, or Rs. 308 million (US$6.3 million) on
maintenance (including cold chain),  and the rest for transportation costs and awareness
building.
4.  Assessfig the Size of Potenfial  T'irge¶  Giroups for zm  1V Vzccime
The following section estimates the size of target groups for a public HIV- 1
vaccination program in both high-risk groups and the general population.  We assume that one
strategy for delivering the vaccine would be to piggyback an HIV immunization program on
existing programs to reach different groups. Thus, the section also examines the levels of
coverage of existing HIV-1  prevention interventions for high-risk groups and the general
population in the southern states, highlighting the gaps in coverage.
Analysis shows that targeting high-risk groups with a vaccine is much more cost-
effective than targeting the entire adult population, regardless of risk (Nagelkerke  and de Vlas
2003). At approximately  one third of the number of vaccines needed,  a higher reduction in
prevalence  is achieved.  However, this would depend on the type of vaccine developed. Early
vaccines may be less than fully effective  and of unknown duration.  In that case, the vaccine
may at best delay infection of high-risk groups and it would be more effective for government
to promote condoms and behavior change interventions.  On the other hand, highly effective
vaccines could potentially be targeted to CSWs only. Vaccinating the general population or
clients of CSWs would be less necessary, although it would protect clients against infected
CSWs, and the general population from clients who are already infected.
Table 2 presents estimates of the size of potential high- and low-risk groups who could
be targeted for a preventive HIV- 1 vaccine in southern India. Estimates of the number of sex
workers in the four states are in the range of 690,000-870,000  and the number of truck drivers
roughly double that number. In contrast, the number of sexually transmitted infection (STI)
patients in the four states in 2001 was only on the order of 165,000. The four southern states
account for about 36 percent of the total STIs recorded in the country  at public facilities (see
Annex Table  1.3). However,  this is a severe underestimate of the true number of persons with
STIs in the population, as more than half of those with symptomatic STIs self-treat or consult
private care and others have asymptomatic infections (often the case with women) and thus do
not seek treatment.  Reliable data on the incidence and prevalence  of STIs is limited, mainly
due to the inadequacy of the surveillance  system (Hawkes and Santhya 2001). NACO
4estimates that the annual incidence of STIs is 5 percent of the adult population, which implies
that about 7 million new STI cases are occurring  annually  in the southern  states. There is very
likely some overlap between the STI patients at government clinics and other high-risk
groups, but government clinics with STI services is clearly one way that government  can
access these groups. A strategy that focused on vaccinating these three high-risk groups in the
four states might therefore require on the order of 2.6 million doses of vaccine.
Table 2. Estimates of the Number of Individuals in Potential Target Groups for a Preventive
HIV-1  Vaccine,  Southern India
High-risk  groups 4  Low-risk groups 4
CSW-  CSW-  Women of  Antenatal
low  high  Truck  STI  Population  Population  Adults  reproductive  clinic
State  estimate  estimate  drivers  patients  0-6  11-14  15-49  age  attenders
Pradhra  184,208  203,000  358,422  27,353  9,673,274  8,955,850  37,121,289  18,504,177  1,483,538
Karnataka  127,318  162,000  266,724  23,537  6,826,168  6,212,630  25,903,503  12,554,834  952,721
Maharashtra  228,376  292,000  525,867  46,947  13,187,087  11,416,766  47,602,107  22,930,801  1,805,679
Tamil Nadu  151,744  212,000  457,131  66,694  6,817,669  7,258,282  30,263,333  15,236,042  1,314,874
TOTAL  691,646  869,000  1,608,144  164,531  36,504,198  33,843,528  140,890,232  69,225,534  5,556,813
Source: CSW: Low estimates are calculated as  1.5 percent of the total female population aged  15-49. High
estimnates  are based on Venkataramana  and Sarada (2001). Truck drivers:  Assumes three drivers for every
registered truck  in the state in 1997, based on SIAM (1999). STI patients:  Based on GOI data on STI clinic
attendees  at public facilities. Population 0-6,  10-14, adults  15-49, women of reproductive age: 2001 Census of
India. Antenatal  clinic attenders: Based on NFHS  1992, drawing on the crude birth rate and the percent who
have at least two tetanus injections in pregnancy.
While vaccination of low-risk populations will not prevent many secondary infections,
if the vaccine is extremely  inexpensive to deliver to low-risk groups (relative to delivery to
high-risk groups) and/or if there are risks of inhibition among high-risk groups that will
reduce the impact of vaccination, then vaccination  strategies might target low-risk
populations. If resources were available to vaccinate all adults  15-49, then  141 million doses
would be necessary.  However,  it isn't clear how this entire population could be reached.
There are more accessible sub-sets of the low-risk population - children under six,
adolescents in the  10-14 age group, and women attending antenatal clinics.  Current coverage
of immunization for children is the base upon which an HIV vaccine could be introduced.
This would require about 45 million doses, assuming a single dose per child and current
coverage of 83 percent (see Table 3). Similarly, about 5 million women in the four states
attend ANC clinics. But coverage is lower at 76 percent. Reaching all ANC women would
require about 7 million doses
The estimates  in Table 2 represent the size of the total unvaccinated population of
different groups, were the vaccine introduced  in 2002.  Once the initial groups are covered, the
HIV vaccination program will require only sufficient vaccine to 'maintain'  coverage levels as
individuals join the cohort or group.
5The estimates in Table 2 are high-end estimates because it is doubtful that everyone in
a given target group could be reached. If the HIV vaccine were distributed via a strategy of
piggybacking on existing health interventions,  then the coverage  of those other interventions
or programs provides an alternative estimate of the number of people who could actually be
reached. Estimates of estimated levels of coverage of the target populations with current HIV
prevention and other services that might serve as conduits for vaccine delivery are in Table 3.
Current coverage of high-risk groups with programs is relatively low-less than a third-
while the coverage of many of the low-risk groups (young children via EPI and antenatal
care) is relatively high-better than 70 percent. This underscores the point that unless
coverage of high-risk groups with other interventions is expanded,  an HIV vaccination
campaign might have limited access to those most vulnerable to infection.
TabEe 3: Percent of the Potential Ta1rget Groups for am lU-l Vaccine Covered  by 1
Preventinm and Other Programs, Southern  lHndia
Sex  Truck  STI
State  workers  driversa  patientsb  EPJc  pwuppd  ANC
Andhra Pradesh  12-14  31  33.6  75.7  0.7  74.8
Karnataka  7-9  15  20.9  91.3  1.0  69.8
Maharashtra  5-7  12  34.3  79.5  4.0  71.0
TamilNadu  16-22  33  31.4  91.9  1.5  90.1
Total/Average  10-12  23  30.5  83.0  2.0  76.0
a. Percent of group that is currently reached by targeted HIV prevention interventions.
b. Percent of those with an STI in the past 12 months who were treated at a government hospital or clinic, from
the 2001 national  Behavioral Surveillance  Survey (BSS). Note, however,  that the sample size of persons
reporting an STI was small (ranging from 59 in  Tamil Nadu to 288 in Andhra Pradesh),  so these estimates are
not precise.
c. Percent "fully immunized", with BCG, DPT (3 doses), OPV (3  doses),  and measles.
d. Percent of married women of reproductive age (MWRA)  who are using condoms for contraception.
Source: See calculations and sources in Annex 1.
S.  stnategec  Use of anE  HH[V-A  Vaceine
Currently, in the absence of a vaccine,  the prevention strategy is based chiefly on
interventions that reduce cascade transmission among and from vulnerable risk groups (Jha
and others 2001, Brunham and Plummer 1990). Each infection prevented among sex workers
prevents "downstreamn"  consequences.  Vulnerable-group  interventions involve peer-based
education of sex workers, their clients and others at high risk (e.g. truck drivers) in the use of
condoms, negotiation skills and treatment of STIs. Worldwide experience has found these
interventions  to be effective.
The HIV-1  vaccine could be delivered either by using the model established by the
EPI program, for example, if it is to be targeted to the general population; or by piggybacking
on other interventions to reach high-risk groups; or on some combination of these two
methods. The vaccine could be made available through the government health care network.
In this case,  ensuring access to vaccination sites and consistent availability of services are
important considerations.  Table 4 summarizes delivery strategies for reaching specific low-
6and high-risk populations with an AIDS vaccine, the size of the groups in southern  India, the
coverage of the programs, and the strengths and weaknesses of targeting each group via the
proposed  strategy.
Delivery strategies  for the general (low-risk) population
If the vaccine were to be targeted to the general population, then it is useful to look at
other programs targeted to this group and how they have performed.  Whether the HIV-1
vaccine is administered  to newborns or to pre-pubescent youth, lessons could be learned from
one of the programs described below in terms of strategies that might be appropriate  for
dissemination of such a vaccine.
Children under six: Expanded  program of immunization. The EPI has a well
articulated service delivery network within the public health care system and is provided at all
government health facilities: hospitals, primary health centers and sub-centers.  In addition to
immunization provided at all times to those who attend the health facility, the routine
immunization program uses a fixed place and time strategy for outreach. In rural areas, the
area covered by a sub-center is divided into four sub-sectors.  A UNICEF cluster survey
(1997-98) found that about 80 percent of all children between 13-24 months of age were
within half a kilometer distance of a scheduled session site. Each sub-sector  is served by the
sub-center itself, and an outreach session (camp) is planned each month at a selected site on a
fixed day of the week. In remote rural areas, a camp approach is used, with health staff and
vaccines visiting the area regularly for a three-month cycle twice a year. In the case of the
pulse polio immunization campaign,  the entire primary health care network is mobilized twice
a year, with the necessary infrastructure  and supplies carefully planned, to deliver services
across the country.
The campaign approach may not be appropriate or feasible  for an HIV-1  vaccine,
however.  Even with a universally accepted program such as polio eradication, there is
considerable  "camp fatigue" that has set in after 4 years of the pulse polio immunization
campaign.  In the case of an HIV-1  vaccine, with the social stigma associated with HIV/AIDS,
it is likely that the resentment against such campaigns would be even more acute.  A much
more appropriate method for reaching vulnerable populations  would be to use existing
intervention prograrns as an outreach vehicle.
7TablMe  4. DeRivery Strategies for an EN-1l  Vacinme au  Southerim  Elindia to Target  Popnngldorms
Coverage
Ongoing  of
Target  Size of  government  ongoing
population  group  program  program  Strengths and  weaknesses
Law-oNp
Children  36.5  EPI  83%  Strengths: High coverage;  most children  are HIV-
under six  million  negative, so little wastage of vaccine.
Weaknesses: If vaccine is of short duration, will not
protect children into adulthood and will have  limited
impact on the epidemic. Even if lifetime duration,
impact on the epidemic  will be delayed until they reach
adulthood.  The vaccine program may  be less efficient
because, few  secondary infections are averted per
injection, on average.
Children II-  33.8  School plus  Only  Strengths: Reaches adolescents shortly before they
14  million  outreach  about  become sexually  active; even a vaccine  of less than
program  46% of all  lifetime duration will have an impact
kids in  Weaknesses: Limited access to these children except
school  through the school system (but enrollment rates are low)
or by community campaigns.  A short duration  vaccine
may not protect them during their most sexually active
years. Also possibly not efficient (see above).
Pregnant  5.6  Antenatal  76%  Strengths: High coverage, reaches women who are
women  million  clinics  sexually active, vaccination of HIV-negative  mother
will prevent transmission  to future children..
Weaknesses  Target group is generally low risk,
preventing few secondary infections.  One quarter of
women not reached,  possibly those most at risk.
il2Ygh-?LsI  --- rz  v
CSW  869,000  Targeted  10-12%  Strengths: Efficient,  as many secondary  infections
HIV  averted.
interventions  Weaknesses: With a less than fully effective vaccine
and if condom use declines with vaccination, epidemic
could get worse. Optimum efforts needed to prevent
'disinhibition'.  Stigmatized groups are difficult to reach.
Targeted intervention has low coverage at present.
Expanding coverage will require capacity building of
NGOs.
Truck  1.6  Targeted  23%  Strengths: Same as CSW. In particular, will prevent
drivers  million  HIV  secondary  infection of spouses and children.
interventions  Weaknesses: Same as CSW.
STI patients  164,531  Public STI  30%  Strengths: A good access point for people from all
treatment  walks of life who are at high risk of  contracting  HIV
and for some, of spreading it.
Weaknesses: Public sector clinics have limited
coverage;  many patients self-treat or seek private care.
Strategy for involving the private sector might be
necessary.
8Children 11-14: Schoolplus outreach  programs. Vaccinating children in the  11-14
age group has the advantage of reaching  adolescents shortly before they become sexually
active; even a vaccine of less than lifetime duration will have an impact. However,  access to
these children is limited to school-based  programs or community campaigns.  There  is also a
possibility that a short duration vaccine may not protect them during most sexually active
years. Notwithstanding this, if vaccinating  children 11-14 is promoted as a strategy, then the
following issues need to be considered.
India has steadily raised primary enrollment rates since independence and today has
the world's second largest education system after China, with  148 million children aged 6-14
attending primary school  in 1997-98  (MOE 2003). Of these, 39.5  million children are in the
upper primary, or 11-14,  age group. However, more than 25 million Indian primary school-
age children are not in school. Two out of five first-grade students will not complete the
primary cycles of 4 to 5 years (depending  on the state), and the learning achievement  of those
graduating  is low. In addition, dropout rates are high: the total dropout rate at primary level
for all of India is 39.6 percent, while at upper primary  level the rate is even higher at 54.4
percent.  The dropout rates for girls are higher--41.3  percent and 58.6 percent, respectively.
Children from poorer families are at a greater disadvantage.  The dropout rate for the poorest
households is about four times that of the richest ones.  There are large gaps in access to
education; quality of education; and learning according to gender, social class, and location.
Even so, with a retention rate at school for children 11-14 of about 46 percent, opportunities
for providing  school-based interventions for this cohort group are substantial.
Pregnant  women: Antenatal clinics. There are about 26 million births annually in
India, or about 5 million in the four Southern States. The best measure of antenatal care is the
percent that have two tetanus shots in pregnancy.  This ranges from 71  to 90 percent in the
southern states and is lower elsewhere (IIPS 2000). Likely the highest risk women do not go
to ANCs. An HIV vaccine could be potentially added to the Integrated Child Development
Scheme (ICDS). An earlier study found that complete  immunization with tetanus toxoid was
recorded for 68 percent of the mothers in the those enrolled in the ICDS program but much
lower at 40 percent for those not enrolled. Coverage was greater in the urban and lower in the
tribal projects. Scheduled castes,  scheduled tribes, backward communities,  and minorities
(groups that have a high priority for social services) had immunization coverage in enrollment
areas that were similar to those of higher castes (Tandon and Gandhi  1992).
Delivery strategies  for high-risk groups
Sex workers and truck drivers: Targeted  HIV interventions. Targeted interventions
comprise a package that includes behavior change communication,  condom promotion,  STI
treatment and creating an enabling environment.  NACO and bilateral donors fund between 20
and 114 interventions per state, implemented by nongovernmental  organizations  (NGOs), that
target higher risk people in each of the Southern states. But geographic coverage  remains
9limited, often to just a few districts in each state. Tamil Nadu, with a very active State AIDS
Control Society and the USAID-funded AIDS Prevention and Control (APAC) project, has
the widest geographic coverage of targeted interventions, but they still are not present in all
30 districts. Until recently, the red-light areas of Mumbai had only two NGOs covering  about
3,000 out of 60,000 sex workers. Even with expansion,  well over half of sex workers remain
outside of NGO programs. Such interventions also lack technical support, operational
research, monitoring and evaluation and training to ensure high quality as well as high
coverage. Tamil Nadu is a partial exception,  and has achieved  relatively high coverage of
enrolled sex workers and truck drivers; HIV-1  levels appear to show some attenuation
(Ramasundaram and others 2001).
ST]/patieists:  [ealth services. Due to the low coverage of government-run  STI clinics
(about 30 percent coverage only), NACO has initiated Family Health Awareness Campaigns
(FHAC) with the objectives of: (i) making people aware of government  services available  for
the treatment of STDs; (ii) facilitating early detection and prompt treatment of STDs; and (iii)
strengthening the capacity of medical  and paramedical professionals in the health care system
to respond to the HIV epidemic.  So far, in the southern states, the FHAC has accomplished
the following (Table 5).
Table S. Populatiions Reached  by the YFamfly  Helgth Awairelmess  Cglmplignf, 2001
Targetpopulation  No. of  attendees  No. ofcases  No.  of cases
(1)  (2)  (2)1(1)  referred  treated
States  Males  Females  Males  Females  M  F  Males  Females  Males  Females
Andhra  16,334,070  16,621,408  1,532,123  2,333,584  9  14  77,256  181,346  77,480  340,272
Pradesh
Kamataka  10,105,594  9,972,361  1,210,268  1,589,525  11  16  83,670  178,873  37,432  137,339
Maharashtra  8,281,381  7,992,458  828,138  2,157,964  10  27  36,2161  557,802  15,375  90,013
Mumbai  1,818,508  1,793,281  87,610  86,916  4  4  450  404  674  2,980
Tarnil Nadu  11,837,949  11,829,270  168,819  665,641  1  5  1,994  12,562  1,774  6,641
Source: Data provided by the State AIDS Control Societies.
STD surveillance  through syndrome-based information from peripheral health
institutions under the primary health care system and etiological  information from STD
clinics is due to be introduced, but neither this nor other forms of STI surveillance  has yet
started (Hawkes and Santhya 2002).
6.  The Costs of an  HfV Vaccination  Rn imtervention iimn  §outhern  lmdnia
The cost of the vaccine product mostly reflects fixed costs (R&D and establishing
manufacturing  capacity); the greater the volume of vaccine procured the lower the unit cost
should be. This will make new vaccines even more affordable  for poorer countries.  In
addition, ensuring that "new" vaccines are actually purchased  and included in immunization
programs will send a strong signal to researchers  and manufacturers that future vaccines they
develop will have a market with effective demand (Batson and Ainsworth 2001; Loevinsohn
1999).
10In estimating the cost of implementing  a publicly-financed  HIV-1  vaccination
program, we have assumed the following:
*  The vaccine would be delivered in a single dose
*  It would not require refrigeration
*  It would not confer any benefits to those already infected, but would not be harmful
*  The cost of the vaccine is Rupees (Rs.) 500 (US$  10) per dose
*  At the time that the vaccine is introduced,  1 percent of the  15-49 age group (1.41 million
adults at high risk and 80 percent of all children aged 11-14 (21.6 million) would be
vaccinated.  This would be in line with the current level of coverage of the EPI in the four
southern  states, and would reflect the combined outcome of school-based and outreach
programs.
*  Maintaining vaccination rates in these two groups would require vaccination of all
entrants to the 1  1-14 year old cohort/year - in other words, all children turning age  11. We
estimate that this is roughly one-fourth of the existing  11 -14 cohort (6.77 million
children).
*  We are making no assumptions about the duration or effectiveness of the vaccine, and
assume no wastage and that the potential vaccinees would be willing to be vaccinated-an
assumption we revisit in the next section.
The total cost of 21.6 million doses of this vaccine for all adolescents age 11-14 and  1
percent of adults would be Rs.  11.5 billion (US$ 230 million), assuming a vaccine cost of
$1  0/dose.  We estimate that the costs of administering the vaccination program in the four
states would be equivalent to half of the annual  cost of administering the polio eradication
program  (Rs. 750 million, or US$  15 million), since polio is administered  in 3-doses and
requires a cold chain, while the HIV vaccine discussed here is a single dose and does not
require refrigeration.  The delivery strategy would be similar to the polio program, with a
combination of fixed facility and outreach programs. It should be pointed out that these
estimates are extremely rough, and would likely underestimate costs quite substantially,  since
certain fixed costs such as establishment  costs, training costs, salaries and so on are not
included. The costs are confined to incremental costs associated with administering the
vaccine.  Thus, the total cost of the initial vaccination  ("catch up") of these groups in the
four southern Indian states  is estimated to cost Rs. 12.25 billion  (US$  245 million).  To
maintain the vaccination rate in the  11-14 year old cohort, an additional  6.77 million  11-year-
olds would have to be vaccinated each year,  at a vaccine  cost of Rs. 3.39 billion  (US  $67.5
million).Table 6. Esfimated Cost of IRFIIV Vaccines and Additional  Costs to Scale-np Preventdon Activities
Rupees  US dollars
Intervention  Level of coverage assumed  (millions)  (millions)
HIV vaccine
Initial vaccination (first year)  80% of children  11-14,  12,250  245
1%  of adults  15-49
Recurrent (maintenance)'  100% of children turning  11  3,390  67.5
(estimated at 25% of the  11-
14 cohort)
Vulnerable group interventions
CSWs (annual)  100% coverage  966.8  19.3
Truckers (annual)  100% coverage  118.4  2.4
ST1.J treatment  Build up to maximum  of
two STI treatment centers
per district
Initial  investment  92  1.8
Annual recurrent cost  56  1.1
Sentinel surveillance  Achieve one sentinel  7  0.13
Annual  site per districtb
Total
Investmentc  13,434.2  268.6
Recurrentd  4,538.2  90.4
Condom promotion  100% condom use by all  27,000  540.6
Recurrent'  men 1549, within and
outside marriage
Total with condom promotion
Investment  40,434.2  808.2
Annual  31,538.2  631.0
Note: a. Includes the cost of vaccines only; delivery costs not included.
b. Requires building 59 additional  sites; this includes investment and recurrent  costs.
c. Assumes that investment would be at least equal to the recurrent costs for interventions for vulnerable
groups and sentinel surveillance. However, it excludes additional capacity building and other start-up costs for
vulnerable  group interventions.
d. Assumes that sentinel surveillance  figures are recurrent.
e. Costs of additional condoms only. Assumes that the public sector finances all of the costs of the shortfall in
condom  use. In fact, a high share of condoms currently used in India is purchased privately through social
marketing.
As noted earlier, because of the possibility of using other channels of preventive
interventions  for delivering an AIDS vaccine, the risk of reversals of other preventive
behaviors (disinhibition)  with a less than fully effective vaccine,  and the complementarities
among interventions  in increasing knowledge and reducing stigma, introduction of an HIV-1
vaccine would have to occur in parallel with a scaling up of other preventive interventions and
of sentinel surveillance.  Table 5 summarizes  the costs of an AIDS vaccine and total costs of
"scaling up" these other HIV preventive interventions in the four states - the vulnerable group
interventions for sex workers and truckers, STI treatment, and HIV sentinel surveillance.
These estimates, for which the calculations are detailed in Annex 2, are extremely rough and
do not include certain fixed costs such as start-up costs, training costs, salaries and so on. The
costs are confined to incremental  investment and recurrent program costs of the additional
12interventions necessary  for the specified coverage and do not include the recurrent costs of
maintaining existing prevention activities.
The investment costs of introducing an AIDS vaccine (under the assumptions made)
and achieving full coverage of vulnerable groups,  STI treatment, and sentinel surveillance
works out to an additional US$0.93  per capita and the recurrent costs to an additional US$
0.32 per capita per year.  This is substantially higher than the US$0.02 - US$0.04 currently
being spent in these states, but the current programs do not include an AIDS vaccine and the
coverage of the existing interventions is low (Jha and Mills 2002) If one were to add the
objective of universal condom use by men in sex within and outside marriage, then the total
investment costs rise to US$2.80 per capita and the recurrent cost to US$2.1 8/capita/ year -
assuming that it is entirely  financed by the government.7
The key point from such costing efforts is that a relatively large increase  in spending
over current levels is required, even if the vaccine cost is as low as Rs. 500 (US$ 10). It will
require considerable political will to make this quantum leap in funding, as well as
considerable assistance from bilateral and multilateral donors. In Andhra Pradesh and
Kamataka, the current leadership  is very keen on tackling the epidemic effectively  and
making a difference. The Chief Minister of Karnataka,  Mr.  S.M. Krishna, has personally
taken over as the Chairman of the Kamataka AIDS Prevention  Society. Such leadership needs
to be supported with adequate epidemiological  information  and programmatic guidance to be
able to make the necessary financial commitment.
7.  Key Constraints to Introducing an HIV Vaccine  and Scaling-up  Prevention
Stigma.  Unless the stigma associated with HIV/AIDS  in India can be reduced,  few
individuals will be willing to be vaccinated and the successful expansion of other preventive
interventions to high-risk groups will be jeopardized.  HIV/AIDS-related  stigma and
discrimination are most closely related to sexual  stigma, since it deals with the sexual
behavior of persons who are considered  to be different from the "norm" (Population Council
2000). It is also strongly linked to gender-related  stigma:  female sex workers are often
stigmatized as carriers and vectors of spread of HIV- I instead of mere links in the broad
network of heterosexual transmission.  Class distinctions are also related to HIV/AIDS, since
poverty increases  vulnerability to the infection. Finally, HIV/AIDS  is a life threatening illness
that people are afraid of contracting.  This interacts with other sources of stigma attached to
the illness and exacerbates the problem.8
7 The Commission on Macroeconomics  and Health (CMH) estimated that the costs to reach about 70
percent coverage for various prevention  activities  in all of South Asia would be about US$0.40 per capita in
2007 and about US$0.51 per capita in 2015 (Jha and Mills 2002). However, the CMH costs were for an
expanded set of activities that did not include  universal condom promotion. The CMH estimates are in line with
the estimates that exclude condom promotion in Table  5.
8  Stigma needs to be dealt with at different levels. First, at the policy and legal level, proper laws and
procedures must be in place to ensure that vulnerable groups are adequately protected from discriminatory
13Low pmblic awareness and  ownership: Raising the levels of awareness of people
about the modes of transmission of HIV-l  and the methods of prevention needs to be
accorded a high priority under the program,  a prerequisite  for any eventual vaccination
program and for the successful  expansion of preventive  interventions.
Vacciine delivery infrastructure.  While the immunization program in India has
accomplished  a good deal, with a steady decline in the number of vaccine-preventable
diseases being reported, overall program performance  has been sub-optimal and uneven
across states (World Bank 2000).  This has been largely due to an erosion of both human
resource and infrastructure  capacity. The cold chain, necessary to refrigerate vaccines  from
procurement to client use, and the transport system have weakened due to aging and
inadequate financing. Better coordination is needed among the departments managing the five
major components of the program: vaccine production, vaccine quality assurance,  service
delivery, disease surveillance,  and research.  As a result, India has been unable to take
advantage of the global technological  advances that have made available new vaccines, such
as hepatitis B. In the absence of national guidelines, states have responded to vaccine-
preventable disease with inefficient campaign approaches,  as in the case of neonatal tetanus,
or by introducing new vaccines on a pilot basis, with insufficient consideration of
epidemiological  factors, costs, institutional capacity,  and sustainability (World Bank 2000).
The public he!alg  defivery sysem The capacity of the public health system would
need to be substantially built up in order to handle an expanded HIV vaccination program.
Having well trained field workers in place, especially designated as HIV/AIDS officers,
would greatly enhance the effectiveness  of the program at the field level.  This has been the
case in other successful programs that have required intensive community-level intervention
such as leprosy elimination, nutrition, and polio eradication.  To re-train the network of polio
officers, for example, and utilize their services for HIV- 1 prevention would be one way of
addressing this problem.
Lack of  plan go iXnvolve 9he privage  secgor, Given the size of the private health sector
in India and its reach in rural areas, excluding the private sector may severely limit the scope
and impact of an HIV vaccination program. In addition, the private sector is believed to be a
dominant source of primary treatment of STIs. Involvement of private physicians would help
measures,  like compulsory screening and testing, compulsory  notification of AIDS cases,  and isolation and
detention of HIV- I positive persons.  Second, at the institutional level, such practices as pre-employment
screening, termination of employment of people living with HIV/AIDS  (PLWHA),  and denial of treatment and
care, must not be allowed  to occur. Third, stigma must be dealt with  in the community context, as local cultural
beliefs and practices may blame the individual for contracting the disease.  This could lead to scape-goating,
punishment and shunning, particularly  of those already suffering from AIDS. In some extreme cases, this has
lead to AIDS-related murders (recent case in Maharashtra).  Finally, stigma must be addressed in the family
context, since the family  is the major source of care and support.  The effect of stigma within the family  is most
severely  experienced by women, who are often rejected by the family and face loss of home and children. The
stigmatization can also extend to the larger family of the people  living with HIV/AIDS,  such as their children
and partners.
14to enhance the coverage of STI services and provide an opportunity for timely intervention,  in
particular the syndromic management. Although the immunization program in India requires
mainly public sector delivery and financing, the private sector and NGOs have both key roles
to play in social mobilization for immunization and in service delivery in areas where the
public sector system is weak, in the cities (private  sector) and in deprived rural areas  (NGOs).
National  capacity  for vaccine trials. At an operational  level, developing countries
such as India offer a different set of challenges with respect to vaccine development and field
trials. There is a lack of trained investigators  (science, clinical trials, ethics,  lab, data
management, project management)  and infrastructure  (clinics, labs, equipment, supplies) in
place to conduct vaccine trials. The regulatory processes to consider and evaluate proposed
experimental vaccine trials are not developed.  A formidable challenge in vaccine
development is the enormous genetic diversity of HIV-1 found world-wide.  Most candidate
vaccines are based on HIV clade B, which is only one of more than ten clades and not the one
that is dominant in India (NIAID 2000). An ideal vaccine must protect individuals against any
genetic subtype of the virus as well as any route of HIV- 1 infection. In addition,  it was found
in Uganda that participants  in vaccine trials feared contracting the infection from the vaccine
(Mugerwaa and others 2002).
Inadequatefundingfor  HIVprevention. Low funding for vulnerable group
interventions is one constraint to high coverage. NACO is currently funded by a World Bank
credit of $191  million over five years. A quarter of this is for targeted interventions to
vulnerable groups.9 In addition,  USAID, the UK Department for International Development
(DflD), and the Canadian International  Development Agency (CIDA) will provide
approximately $71  million over the same period, mainly focusing on vulnerable groups. All
told, this means approximately 2 US cents per capita per year for prevention of HIV in
vulnerable  groups, or approximately  12 US cents in purchasing power parity terms. In
Karnataka, for example, the budget for targeted interventions for the year 2002-03  is about
Rs.12,140,000  (US$245,000),  which works out to about 4 US cents per capita.  Even with the
20 new interventions planned with an additional expenditure of Rs. 17,200,000
(US$350,000),  this is a woefully inadequate amount to be spending in a state that has an HIV-
1 prevalence rate of 1.68percent in ANC sites.
Capacity  to design, implement, monitor, and  evaluate  programs. There is a huge
need for capacity building of all levels of workers to design, implement, monitor, and evaluate
HIV programs:  State AIDS Control Society officers; NGO personnel;  field workers; and
health workers.  Some efforts have worked in different states but they need to be scaled up
significantly,  and need to be replicated in other states where such initiatives have not yet been
undertaken.  Current coverage of sentinel surveillance  at both ANC sites and STI sites is very
9The current allocation  represents an improvement.  Under an earlier World Bank credit from 1992-1999,  NACO  spent
about 40 percent of funds on blood safety,  37 percent on general  information  campaigns,  and 7 percent on  STI control  Lack
of emphasis  on vulnerable groups  is not unique to India,  however.
15low (30 percent and  19 percent, respectively).  There is no functioning STI surveillance  system
in place, and no data on either STI or HIV-1  from the private sector, where the majority of
service providers operate. Monitoring and evaluation capacity is extremely weak..  The state
with the best record is Tamil Nadu, where sentinel surveillance and six waves of behavioral
surveillance sponsored by USAID-funded APAC project have  successfully tracked the
epidemic,  levels of awareness, and behavior change. Such data has helped TNSACS to set
priorities for focused interventions.  Andhra Pradesh and Karnataka are now beginning to
benefit from this type of input from the DfID- and CIDA-funded programs in their states, but
much more needs to be done.
$.  lRecommheda1ToD1s
This study gives rise to several recommendations.  First, there is a need to more in-
depth case studies on the ability and willingness of various vulnerable groups to accept and
access a possible HIV-1  vaccine.
Second, there is a need to expand implementation of prevention programs, which will
remain critical even if an effective vaccine is eventually available.
Third, the common inputs to vaccines and prevention require considerable
strengthening. These include:
o  Better surveillance  of the trends in HIV-1  by expanding the number and quality of sentinel
surveillance among ANC and STI clinic attendees to every district.
o  As sentinel surveillance is poor at predicting levels (it is better at detecting changes in
prevalence),  a few large, longitudinal studies of well-characterized  population cohorts of
HIV-1  negative people to measure the incidence of HIV- 1 (the number of new infections).
These are also required to better understand transmission dynamics in different states and
thus help inform the relative importance of targeting vaccines.
o  Common tools of mapping at local levels (i.e. district or below) of populations who would
require preventive interventions,  including vaccines.
o  Strong human resource development of a cadre of HIV/AIDS  officers who can work like
the polio officers in India to: conduct surveillance and improve its quality; work and train
NGOs to conduct peer group interventions;  and strengthen  STI syndromic management.
O  Ongoing evaluation activities to identify gaps in coverage (for example, continuously
providing  denominators of"unreached populations"  as do immunization programs) and to
help monitor any adverse behavior change that could occur from introduction of vaccines
and/or availability of anti-retroviral  therapies.
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18Annex  1. Estimates  of the Coverage  of Public Health Interventions in Key Groups
Annex Table 1.1.  Estimated coverage  of CSW interventions
Number of
Number of  Number of  CSW
CSWs (low  CSWs (high  interven-  Population  Coverage  Coverage
State  est.)  est.)  tions  covered  (high)  (low)
Andhra Pradesh  184,208  203,000  17  25,000  14%  12%
Karnataka  127,318  162,000  4  12,000  9%  7%
Maharashtra  228,376  292,000  15  15,000  7%  5%
Tamil Nadu  151,744  212,000  33  33,000  22%  16%
Southern states  691,646  869,000  85,000
Source: Authors, based on Venkatramana  and Sarada (2001)/
Annex  Table 1.2. Estimated coverage  of trucker interventions
Number of
Estimated  number oftTruck  trucker  Truckers
State  drivers'  interventions  covered *  Coverage
AndhraPradesh  358,422  22  110,000  31%
Kamataka  266,724  8  40,000  15%
Maharashtra  525,867  13  65,000  12%
TamilNadu  457,131  30  150,000  33%
Southern states  1,608,144  73  365,000  23%
Note: a. Estimated at 3 times the number of trucks registered  in  1997.
Source: Authors, based on Automan  (2001)
Annex Table 1.3. Number of reported STI cases  in public health facilities,  2001
Urethral  Vaginal  Inguinal
Genital ulcer  discharge  dis-  swelling 2 Others  Total
State  |  M  I  F  I  M  I  F  I  charge |  MI1  F  I  M  I  F  I  M  I  F  I  Total
Andhra
Pradesh  2,774  655  3,064  492  3,819  344  66  10,920  5,219  17,102  10,251  27,353
Karnataka  1,668  531  1,461  482  7,746  167  35  8,101  3,346  11,397  12,140  23,537
Marrashtra  2,403  791  2,059  1,282  22,211  164  56  6281  11,700  10,907  36,040  46,947
Tamil  4,821  3,221  4,155  2,244  16,682  1,120  742  20,716  12,993  30,812  35,882  66,694
Nadu
Southern
states  11,666  5,198  10,739  4,500  50,458  1,795  899  46,018  33,258  70,218  94,313  164,531
India  27,348  12,666  24,690  9,542  126,190  2,866  1,446  128,162  80,970  183,006  230,724  413,790
Note: a.  Swelling of the groin.
Source: NACO (2002).  "Surveillance  for STD Cases in India,  January 2001 to December 2001". MOHFW,
Delhi.
19Annm¢et  Taable  1.4. Percenit of Those with an 5TR Seeinig Tireatmnnent in a Goverrnmmeint
Hllospital/CHinic  duriAng the Last Episode
(n=number  who reported STI or symptoms  in the last  12 months in the sample)
Urban  Rural  Combined'
State  Male  Female  Total  Male  Female  Total  Male  Female  Total
Andhra Pradesh  24.2  28.6  26.4  45.8  23.5  35.8  41.1  24.8  33.6
(62)  (63)  (125)  (83)  (68)  (151)  (155)  (133)  (288)
Karnataka  28.6  18.8  20.2  29.7  13.2  21.3  29.6  15.9  20.9
(14)  (80)  (94)  (37)  (38)  (75)  (60)  (102)  (162)
Maharashtra  30.8  54.8  51.2  14.8  27.3  23.2  18.5  39.8  34.3
(13)  (73)  (86)  (27)  (55)  (82)  (43)  (124)  (167)
TamilNadub  33.3  21.1  25.8  40.0  31.6  34.5  37.4  27.9  31.4
(12)  (19)  (31)  (10)  (19)  (29)  (21)  (38)  (59)
India (mean)  28.2  24.5  25.6  30.5  18.9  22.7  28.6  19.6  22.4
Standard Deviation  16.9  17.1  14.8  15.6  14.4  12.1  14.9  13.1  12.0
Median  30.8  24.6  26.2  31.7  19.8  24.1  31.6  19.7  25.1
Range  9.7-  9.1-  10.6-  6.7-  0.0-  7.7-  7.1-  9.6-  10.0-
75.0  75.0  68.0  60.0  65.6  56.5  64.1  57.2  58.9
(n)  (490)  (1102)  (1592  (662)  (1378)  (2040)  (1197)  (2681)  (3878)
Note: a. Weighted figures. b.  Tamil Nadu and Pondicherry.
Source: NACO (2001).
Annmmexr  Tabe  R.S. Coverage of ]Different Vaccines  (peirceimS) 1999
Immunization Status
Par-
State  BCG  DPTI  DPT2  DPT3  OPVI  OPV2  OPV3  Measles  Full  tial  None
Andhra  92.6  95.0  93.4  92.0  94.6  93.4  91.7  78.1  75.7  21.5  2.8
Pradesh
Karnataka  97.5  97.9  97.8  97.0  97.8  97.5  96.7  93.2  91.3  7.4  1.3
Maharashtra  98.2  99.3  97.0  96.2  99.1  96.6  96.0  82.0  79.5  20.1  0.4
Tamil Nadu  97.5  98.8  98.5  97.6  98.7  98.0  97.6  93.6  91.9  6.9  1.2
India  85.9  87.6  84.7  80.8  87.7  85.0  81.0  66.5  63.3  27.1  9.6
Source: Government of India/MOHFW  (1999).
Aunea1I  Table  1.6. Percent of Curr¢ently Married Women using Condoms fifr Contraception,  11999
State
Age  Andhra Pradesh  Karnataka  Maharashtra  Tamil Nadu
15-19  0.2  0.3  1.2  0.5
20-24  1.0  1.0  6.7  1.9
25-29  0.6  1.3  5.4  2.4
30-34  1.7  1.4  5.4  1.8
35-39  0.6  1.6  2.0  1.5
40-44  0.0  0.7  1.9  0.8
45-49  0.0  0.6  0.9  0.0
Total  0.7  1.0  4.0  1.5
Source: NFHS,  1992-93 and  1998-99, from IIPS (1995,  2000).
20Annex  2. Estimating the Costs of Additional Coverage ("scaling up") of HIV Prevention
Programs in Southern India
2.1  Targeted  interventions to high-risk  groups
NACO guidelines for costing interventions,  which are largely based on experience in
some of the southern states, suggest that the annual cost per person reached is Rs. 1,208.05
per CSW and Rs. 94.7 per truck driver (NACO 1999).  Bringing coverage to  100 percent for
these two groups would require reaching  (approximately)  800,000  additional sex workers
(using the high estimates of the number of CSWs in these states) and  1.25 million additional
truckers,  at a total annual cost of Rs.  966.8 million  (US$  19.3 million)  for CSW and Rs.
118.4 million  (US $2.4 million)  for truckers. These are the annual recurrent  costs for the
coverage of the additional  interventions and exclude training or capacity building to NGOs
that would be necessary investments in wider implementation.
2.2  STI treatment  services
The estimated cost of scaling up an STI control program  is based on the costing
worked out by the Maharashtra  State AIDS Control  Society. The cost of raising the number of
STI sites per district to two would cost about Rs. 23 million per state or US$0.5 million in
investment costs.'0 This would include the costs of goods (Rs.  1.7 million or US$300,000);
equipment (Rs. 6.9 million or US$0.15  million); vehicles and furniture  (Rs.  1.5 million or
US$0.03 million); and medicines  (Rs.  12 million or US$0.25  million). The recurrent costs per
state for these additional  STI clinics would be about Rs.  14 million or US$0.3  million.
Together across the four states, this amounts to investment costs  of Rs. 92 million  (US$  1.8
million)  and annual recurrent costs  of Rs. 56 million (US$  1.1  million) for the additional
clinics.
2.3  Sentinel surveillance
In order to establish a minimum of one sentinel surveillance site in each district, an
additional 59 sentinel sites need to be set up. An estimate made by the' Karnataka  State AIDS
Control Society in their Action Plan indicates that an additional sentinel site would cost Rs.
110,000 (honorarium for personnel, transportation,  training and equipment).  The cost of 59
additional  sites would amount to Rs. 6,490,000 or US$130,000.
2.4  Condom distribution
The total population of adults  15-49 in the four states is roughly  140 million, of which
roughly half, or 70 million,  are men (see Table 2 of the text). If one were to establish the goal
of condom use in every sexual act (including universal  condom use in marriage, even if one
partner is already sterilized) and assuming an average need of 100 condoms  per man per year,
then the total requirements  for condom distribution  (through public or private sources) would
be 7 billion condoms.
10  Insuring two STI sites per district would require an additional 23-30 sites per state.
21For fiscal year 1999-200,  distribution of condoms in the southern  states through
NACO (including socially marketed condoms and those commercially  distributed) is
estimated to be 25 percent of the national total of roughly 650 million condoms, or  162.5
million. In addition, about 80 million condoms are distributed free of charge in these states
through the Ministry of Health and Family Welfare.  This brings the total current distribution
to 242.5 million condoms annually.
The shortfall between actual condom distribution and  100 percent coverage is
therefore 6.76 billion condoms. At Rs. 4 per condom, the total cost would be about  R1s. 27
bhRRion  or 1US$ 540o6 miRllon a yeair.
Due to the low usage rates of condoms, the concern is whether the distribution under
RCH and AIDS control is enough and whether it should be scaled up to cover all the persons
in the target cohort or restricted to a lesser percentage with a suitable effort to increase social
marketing and commercial distribution.  Over the years, condoms have become associated
with family planning, and couples who have chosen more permanent methods such as
vasectomy or tubal ligation would not feel it necessary to use condoms. To promote condoms
for reasons other than family planning would take a particularly  rigorous behavior change
communication program aimed at the general population. NACO figures indicate that twice
the number of condoms was being socially and commercially  marketed in the southern states
as was freely distributed, indicating that there is a willingness to pay for condoms  among
certain segments of the population. However, this may not apply to all segments.  These are
some of the concerns that need to be addressed.
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